Aziz Kabeer 4

4 · AN2 Therapeutics, Inc. · Filed Apr 10, 2026

AI-generated summary of this filing

Updated Apr 11, 2026

AN2 Therapeutics (ANTX) Director Aziz Kabeer Receives Award

What Happened

Aziz Kabeer, a member of AN2 Therapeutics' board of directors, was issued 3,775 shares on 2026-04-10 as a grant/award (transaction code A). The filing reports an acquisition price of $0.00 (shares issued in lieu of cash compensation); the reported transaction value is $0.
All 3,775 shares vest immediately per the filing (see footnote F1). This is an issuance of compensation rather than an open‑market buy or sale.

Key Details

Transaction date: 2026-04-10; Price reported: $0.00 per share (award issued in lieu of cash).
Shares acquired: 3,775; total reported transaction value: $0.
Shares owned after transaction: not specified in this Form 4 filing.
Relevant footnotes: F1 — shares issued in lieu of cash under the non‑employee director compensation policy and all shares vest immediately. F2/F3 — disclosures about certain shares being held by Adjuvant funds and potential shared voting/dispositive power; those notes disclaim beneficial ownership except to the extent of pecuniary interest.
Filing timeliness: filed on 2026-04-10 for a transaction on the same date (no late filing indicated).

Context

Awards issued in lieu of cash are a form of routine director compensation and reflect receipt of equity rather than a market purchase; immediate vesting means the director has full ownership of these shares upon issuance.
Such compensation grants do not necessarily indicate the insider’s market view and should be considered alongside other insider transactions and company developments.

Form 4

Period: 2026-04-10

Director

Transactions

Holdings

Footnotes (3)

[F1]Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
[F2]Shares are held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
[F3]Shares are held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

Signature

/s/ Lucy Day, Attorney-in-Fact for Kabeer Aziz|2026-04-10

1 file